Top 10 European Pharmaceutical Tech Companies

Swiss giant Novartis (CHF 45.7B revenue) has staked its future on radioligand therapy (RLT) and gene therapies after spinning off Sandoz. Its Kymriah CAR-T therapy remains the gold standard for relapsed paediatric leukaemia, and the Basel-based AI hub employs 500+ data scientists mining real-world evidence to accelerate approvals.

Basel-based Roche (CHF 58.7B revenue) dominates personalised oncology diagnostics and therapy through its dual pharma-diagnostics model. Its Foundation Medicine unit has genomically profiled 700,000+ tumour samples, and Roche's multispecific antibody platform produced tiragolumab, among the most clinically active immuno-oncology combinations in 2025.

Mainz-based BioNTech (€17.3B revenue at peak) fundamentally rewrote the rules of vaccine development with its mRNA COVID-19 vaccine, produced in 11 months. Its oncology pipeline now includes 20+ mRNA cancer vaccine candidates, with individualised neoantigen vaccines for melanoma showing 44% reduction in recurrence in Phase 2/3 trials.

Belgian biopharmaceutical company (€5.5B revenue) specialising in neurology and immunology with blockbusters Bimzelx (IL-17A/F inhibitor) and Fintepla for Dravet syndrome. UCB's bepranemab antibody for Alzheimer's tau pathology is among Europe's most-watched Phase 2 readouts expected in 2026.

Hamburg-based drug discovery platform (~€800M revenue) running the world's largest open-innovation pharma network. Evotec's AI engine has analysed 500B+ data points across target identification, compound optimisation and clinical prediction, cutting average hit-to-lead timelines by 65%. Partners include Bayer, Novo Nordisk and Bristol Myers Squibb.

Oxford-born AI-first pharma company that became the first to design drugs that entered clinical trials using purely AI-generated molecular structures. Exscientia's Centaur Chemist platform reduces preclinical timelines from 4.5 years to under 12 months, and its 2026 pipeline includes AI-designed kinase inhibitors and bispecific antibody fragments.

Paris-based AI biotech (valued at $1B+) that pioneered federated learning for clinical data — allowing AI models to train on hospital data without the data ever leaving the institution. Owkin's MSI biomarker predictor is approved for colorectal cancer diagnosis in France, and its predictive survival models are embedded in 25+ European oncology centres.

Utah-founded but with major European operations including the Cyclica and Vividion acquisitions, Recursion runs the world's largest biological image dataset — 22PB — processed by custom AI models to predict drug-disease relationships. Its 2025 partnership with Roche covers 40 small-molecule programs targeting oncology and neurological diseases.

Cambridge-based rare disease AI company using its Healnet knowledge graph to repurpose existing approved drugs for 7,000+ rare conditions that currently lack treatments. Healx's pipeline includes HLX-0117 for Fragile X syndrome — the first AI-identified rare disease drug to reach Phase 2 — and partners with 20+ patient advocacy organisations.

Swiss giant Novartis (CHF 45.7B revenue) has staked its future on radioligand therapy (RLT) and gene therapies after spinning off Sandoz. Its Kymriah CAR-T therapy remains the gold standard for relapsed paediatric leukaemia, and the Basel-based AI hub employs 500+ data scientists mining real-world evidence to accelerate approvals.

Basel-based Roche (CHF 58.7B revenue) dominates personalised oncology diagnostics and therapy through its dual pharma-diagnostics model. Its Foundation Medicine unit has genomically profiled 700,000+ tumour samples, and Roche's multispecific antibody platform produced tiragolumab, among the most clinically active immuno-oncology combinations in 2025.

Mainz-based BioNTech (€17.3B revenue at peak) fundamentally rewrote the rules of vaccine development with its mRNA COVID-19 vaccine, produced in 11 months. Its oncology pipeline now includes 20+ mRNA cancer vaccine candidates, with individualised neoantigen vaccines for melanoma showing 44% reduction in recurrence in Phase 2/3 trials.

Belgian biopharmaceutical company (€5.5B revenue) specialising in neurology and immunology with blockbusters Bimzelx (IL-17A/F inhibitor) and Fintepla for Dravet syndrome. UCB's bepranemab antibody for Alzheimer's tau pathology is among Europe's most-watched Phase 2 readouts expected in 2026.

Hamburg-based drug discovery platform (~€800M revenue) running the world's largest open-innovation pharma network. Evotec's AI engine has analysed 500B+ data points across target identification, compound optimisation and clinical prediction, cutting average hit-to-lead timelines by 65%. Partners include Bayer, Novo Nordisk and Bristol Myers Squibb.

Oxford-born AI-first pharma company that became the first to design drugs that entered clinical trials using purely AI-generated molecular structures. Exscientia's Centaur Chemist platform reduces preclinical timelines from 4.5 years to under 12 months, and its 2026 pipeline includes AI-designed kinase inhibitors and bispecific antibody fragments.

Paris-based AI biotech (valued at $1B+) that pioneered federated learning for clinical data — allowing AI models to train on hospital data without the data ever leaving the institution. Owkin's MSI biomarker predictor is approved for colorectal cancer diagnosis in France, and its predictive survival models are embedded in 25+ European oncology centres.

Utah-founded but with major European operations including the Cyclica and Vividion acquisitions, Recursion runs the world's largest biological image dataset — 22PB — processed by custom AI models to predict drug-disease relationships. Its 2025 partnership with Roche covers 40 small-molecule programs targeting oncology and neurological diseases.

Cambridge-based rare disease AI company using its Healnet knowledge graph to repurpose existing approved drugs for 7,000+ rare conditions that currently lack treatments. Healx's pipeline includes HLX-0117 for Fragile X syndrome — the first AI-identified rare disease drug to reach Phase 2 — and partners with 20+ patient advocacy organisations.